Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Wednesday . The stock had previously closed at $29.44, but opened at $28.22. Ascentage Pharma Group International shares last traded at $28.92, with a volume of 1,221 shares.

Analysts Set New Price Targets

AAPG has been the topic of a number of analyst reports. Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. Piper Sandler began coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 target price on the stock. Oppenheimer initiated coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Finally, BTIG Research began coverage on Ascentage Pharma Group International in a research note on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus target price of $48.50.

Ascentage Pharma Group International Stock Up 2.3%

The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The business’s 50 day moving average is $32.49 and its two-hundred day moving average is $36.71.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International during the 3rd quarter valued at $96,000. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International during the 3rd quarter valued at about $204,000. Chevy Chase Trust Holdings LLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter worth about $227,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Finally, Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.